Myostatin Inhibition Enhances the Effects of Exercise on Performance and Metabolic Outcomes in Aged Mice

Nathan K. LeBrasseur(Pfizer (United States)), Teresa M. Schelhorn(Pfizer (United States)), Barbara Bernardo(Pfizer (United States)), Patricia G. Cosgrove(Pfizer (United States)), Paula M. Loria(Pfizer (United States)), Thomas A. Brown(Pfizer (United States))
The Journals of Gerontology Series A
May 29, 2009
Cited by 174Open Access
Full Text

Abstract

The objective of this study was to examine the effects of short-term exercise training, myostatin inhibition (PF-354), and exercise+PF-354, all relative to a vehicle control, on performance and metabolic measures in 24-month-old mice. At study termination, PF-354-treated mice exhibited significantly greater muscle weights. Performance measures revealed that exercise+PF-354 increased treadmill running time and distance to exhaustion (more than twofold) and increased habitual activity. Measures of strength were not different; however, all treatment groups demonstrated more than 30% reductions in muscle fatigue. Metabolic measures showed that basal metabolic rates were higher in PF-354- and exercise+PF-354-treated mice, and exercise and exercise+PF-354 groups exhibited significantly greater insulin sensitivity. PF-354 was associated with decreased Smad3 phosphorylation and increased peroxisome proliferator-activated receptor gamma coactivator-1alpha expression and, similar to exercise, decreased MuRF-1. The data suggest that the combination of exercise training and myostatin blockade may significantly improve physical function and whole-body metabolism in older individuals.


Related Papers

No related papers found

Powered by citation graph analysis